CCM
BNR

CAAS Capital Management’s Burning Rock Biotech BNR Stock Holding History

CAAS Capital Management’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,000
Closed -$1.89M – 484
2020
Q2 		$1.89M Buy
+7,000
New +$1.92M 0.06% 216

Other funds holding BNR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

CAAS Capital Management's BNR Position: Q3 2020 in Review

CAAS Capital Management sold out of Burning Rock Biotech (BNR) in Q3 2020, closing a stake of 7,000 shares — an estimated $1.89M sold.

CAAS Capital Management first reported a position in BNR in Q2 2020 and held it in 1 quarter. The position peaked at $1.89M in Q2 2020. 38 funds tracked by Wall St. Rank hold BNR as of Q3 2020.

  • CAAS Capital Management reported no remaining Burning Rock Biotech position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 7,000 Burning Rock Biotech shares in Q3 2020, an estimated $1.89M.
  • CAAS Capital Management first reported a position in Burning Rock Biotech in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's Burning Rock Biotech position peaked at $1.89M in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.